INTRODUCTION
Portal vein tumor thrombus (PVTT) occurs in a sub stantial proportion of patients with hepatocellular carcinoma (HCC), with 44% of the patients presenting at the time of death and about 10%40% at the time of diagnosis [1] . In particular, HCC with tumor thrombus in the main portal trunk or the opposite side portal branch represents an endstage condition with poor prognosis due to malignant hepatic tumor cells occluding the blood flow and deteriorating the portal hypertension [2] , with a perioperative mortality rate of 0%28% and a 5year overall survival (OS) rate of 0%26.4% [3] . As main PVTT (MPVTT) is contraindicated to surgical resection and transplantation due to a high tumor recurrence rate, no standard treatment has been established [4] . Threedimensional conformal radiotherapy (3DCRT) has shown survival benefits in HCC patients with PVTT [5] . However, blood flow to the obstructed main portal vein (MPV) cannot be restored immediately with radiotherapy alone. Further, PVTT is generally considered a contraindication for TACE due to the interruption of hepatic arterial flow which could result in a large segment of hepatic necrosis in patients whose blood supply is already compromised [6] . Furthermore, tumor thrombus in the MPV could not be effectively controlled by TACE combined with intraportal stent, leading to a shorter stent patency rate along with increased risk of liver necrosis and treatmentrelated death [7] . Thus, the use of TACE is limited to only selected group of patients with good hepatic function and adequate collateral circulation around the occluded portal vein [8] . Given the limitation of TACE, transarterial radioembolization (brachytherapy) has emerged as a safer and more effective treatment for HCC with PVTT than TACE [9, 10] . Endovascular brachytherapy (EVBT) by interstitial implantation of iodine125 ( 125 I) seeds has been studied extensively [1113] . Combined endovascular implantation of 125 I seed strand with stent placement and TACE provided longterm survival benefits and increased patency rates of the stent [14, 15] . Although sorafenib has been recommended as the firstline treatment for advancedstage disease (i.e., Barcelona Clinic Liver Cancer (BCLC) stage C with PVTT), the survival outcomes obtained were also only modest [16] . Recent studies have reported survival benefits in patients with PVTT who underwent combination treatments of TACE with sorafenib, radiotherapy with sorafenib, and hepatic arterial infusion chemotherapy with sorafenib [1719] . A recent study by Huang et al [20] reported survival benefit of chemoembolization plus 125 I seed implantation in unresectable hepatitis Brelated HCC with PVTT. However, reports of such combined therapeutic strategies aiming at MPVTT are obscure. Endovascular implantation of 125 I seeds strand and portal vein stenting followed by TACE combined with sorafenib could improve the progression free survival (PFS) of HCC patients with MPVTT [21] . In the present retrospective study, we aimed to evaluate the safety and efficacy of EVBT combined with stent placement, TACE, and sorafenib compared with TACE with sorafenib in the treatment of HCC patients with MPVTT.
MATERIALS AND METHODS

Study design
This was a singlecenter, retrospective study conducted on advanced HCC patients with MPVTT from January 2009 and December 2015. The study protocol was approved by the institutional ethics committee of the respective hospital involved. MPVTT was detected based on the presence of lowattenuation intraluminal mass expanding the main portal vein, and/or filling defects in the main portal vein, as determined by three phase dynamic computed tomography (Figure 1 ).
Patient selection and grouping
Patients aged between 1875 years with unresectable HCC or unfit for liver transplantation and percutaneous frequency ablation according to the BCLC classification were included. All patients had Child-Pugh classification grade A or B, Eastern Cooperative Oncology Group (ECOG) performance status of 02, and MPVTT confirmed by demonstration of tumor thrombus in MPV and HCC in threephase dynamic CT images 7 d before treatment.
Patients who had undergone surgery, localregional therapies (radiofrequency ablation, percutaneous ethanol injection, or 125 I seed implantation), liver transplantation, previous sorafenib therapy, systemic chemotherapy, intraarterial chemoinfusion, or TACE; patients with serious medical comorbidities such as encephalopathy and uncorrectable bleeding diathesis; patients who currently had or had a history of malignant tumors in addition to HCC; and those with intrahepatic portal vein completely occluded by HCC, tumor thrombus extending into the superior mesenteric vein (SMV) or splenic vein (SV), advanced liver disease, or contraindication for chemoembolization (HCC burden > 70% of total liver volume or high flow intrahepatic arterial venous shunt) were excluded from the study.
Written informed consent was obtained from all eligible patients who were recommended to choose either combined EVBTstentingTACEsorafenib (group A) or TACEsorafenib (group B) treatment. TACE sorafenib was recommended for patients who refused EVBTstentingTACEsorafenib treatment.
Treatment procedures
Sorafenib treatment: Sorafenib (Nexavar; Bayer, Leverkusen, Germany) was taken for 3 d after the first TACE procedure at a recommended dose of 400 mg twice daily in all patients and with a 3d interruption after subsequent TACE cycles (30 d 
Intra-MPV stent and
125
I seed strand implantation: In group A patients, the patent secondorder branch of the intrahepatic portal vein in the unaffected side with hepatopetal flow was punctured with a 22gauge Chiba needle (Cook, Inc., Bloomington, Indiana) under ultrasound guidance, followed by insertion of a 0.018inch wire (Cook Inc.) into the portal vein. A 5F calibrated pigtail catheter (Cook Inc.) was used to gauge the pressure in filling splenic mesenteric veins and portography was performed to measure the diameter and length of the obstructed MPV (stenosis). The number of 125 I seeds to be implanted was calculated by the following formula: N = Length of obstructed MPV (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4F catheter continuously to construct a 125 I seed strand. After 50 U/kg heparin (XinYi, Shanghai, China) was administered intravenously, two 0.035inch, 260cmlong stiff wires (Terumo) were inserted into the superior mesenteric vein through the 7F sheath. After the sheath had been removed, the outer cannula of the NEFF set and a selfexpendable stent of appropriate size were introduced to the MPV over one of the stiff wires, respectively. The stent was deployed from the distal MPV into the proximal patent intrahepatic portal vein. The 125 I seed strand was delivered to the target position via outer cannula of the NEFF set and released between the stent and MPV (Figure 2A and B). Portography and pressure measurement were repeated.
TACE procedure
Segmental TACE was performed by experienced interventional radiologists immediately after stent and 125 I seed implantation. Regardless of the type of HCC (unilobar or bilobar), all feeding arteries of tumor identified by angiography of the celiac, hepatic, superior mesenteric, left gastric, and bilateral inferior phrenic arteries were chemoembolized using a 5F RH catheter (Cook). The target artery was catheterized with a 2.7F microcatheter (Renegade, Boston Evaluation Criteria in Solid Tumor (mRECIST) [22] . The primary endpoints were OS and time to progression (TTP). OS was defined as the period from the day of the procedure to patients' death or to their last followup. TTP was defined as the period from the day of the procedure until the radiologic confirmation of tumor progression in liver parenchyma. For HCC in liver parenchyma, disease control rate (DCR) was defined as the percentage of patients with complete response (CR), partial response (PR), or stable disease (SD). Tolerance and AEs were measured as secondary endpoints. Sorafenib and TACErelated AEs were monitored using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 [23] . As MPVTT would increase the incidence of tumor dissemination, elevate portal vein pressure, and impair the liver functional reserve, occurrence of events like intrahepatic HCC spread, variceal bleeding, and liver function decompensation was also compared between the two groups. Pfizer, NY) and 520 mL of iodized oil (Lipiodol Ultrafluide, Laboratoire Guerbet, AulnaysousBois, France) was infused at a rate of 0.51 mL/min through the microcatheter until stasis flow in the tumor vascularity was achieved. Finally, gelatin sponge (Jingling, Jiangsu, China) was used to embolize the feeding artery of the tumor.
Statistical analysis
Post-procedural evaluation
Single photon emission computed tomography (SPECT) combined with CT (SPECT/CT) scan was performed on day 1 of the therapy to evaluate the distribution of radiation by the 125 I seed strand implanted in group A patients ( Figure 2C ).
Follow-up and repeat TACE
The total number of hospitalization days was 57 d, which were prolonged if grade 34 adverse events occurred. All the patients were followed every 30 d until death or till March 1, 2016. Repeat TACE with the same protocol was performed upon detection of residual tumors or new lesions in all patients. diseasefree survival were analyzed using the Kaplan Meier curves and logrank test. A P-value of less than 0.05 was considered statistically significant. Variables with P < 0.05 were chosen for multivariate analysis using the Cox proportional hazards model. Regression analysis was used to determine independent predictors of survival. Sex, age, type of tumor, HCC maximum diameter, degree of MPVTT, ChildPug class, ECOG performance status, etiology of liver disease, serum alfafetoprotein level, and extrahepatic metastasis were considered within the propensity model. Propensity score matching analysis was performed, with a matching ratio of 1:1 for two groups, using the nearestneighbor matching method with a caliper distance of 0.2 without replacement.
Efficacy and safety endpoints
RESULTS
Baseline characteristics of patients and tumors
A total of 83 unresectable HCC patients were identified. Of them, 15 patients were excluded due to reasons listed in Figure 3 . Finally, 68 patients were included in this study (group A, n = 37; group B, n = 31). Baseline characteristics before score matching are shown in Table 1 . After propensity score matching, we created 24 matched pairs of patients in Table 2 .
Technical success
The 125 I seeds strand and stent placement procedure was completed in all patients in group A (technical success rate, 100%) and the TACE procedure was completed in all patients in both groups.
OS and TTP in the entire cohort
The median followup durations were 12.7 mo and 5.9 mo for the prematched groups A and B, respectively. The 6, 12, and 24mo survival rates were 88.9%, 54.3%, and 14.1% in group A, and 45.8%, 0%, and 0% in group B, respectively (P < 0.001). However, there were no procedurerelated deaths. KaplanMeier curves for survival outcomes in the two groups showed significantly higher OS in group A compared to group B (12.3 mo vs 5.2 mo; P < 0.001; Figure 4A ).
The median TTP was longer (9.0 mo) in group A, compared to group B (3.4 mo) (P < 0.001; Figure 4B ).
OS and TTP in the matched cohort
In the propensity scorematched cohorts, the median OS was longer in group A than in group B (10.3 mo vs 6.0 mo; P < 0.001; Figure 4C) . Similarly, the median TTP was significantly longer in group A than in group B (9.0 mo vs 3.4 mo; P < 0.001; Figure 4D ).
Predictive factors for OS in the entire cohort
In multivariate Cox analysis, treatment regimen (HR = 0.18, P < 0.001) was identified as an independent predictor of OS for group A vs group B (Table 3) .
Iodine-125 seed dose and stent patency
After stent placement in group A patients who were implanted with 17.2 ± 4.9 (range, 1031) 125 I seeds, the mean pressure of MPV dropped from 38.1 ± 5.8 cm H2O (range, 2346 cm H2O) to 32.0 ± 5.6 cm H2O (range, 1637 cm H2O) (P = 0.002). The estimated mean accumulated dose (R = 10 mm, z = 0, 240 d) was 62.9 ± 2.3 Gy (range, 57.465.3 Gy). Stent occlusion was observed in 9 (24.3%) patients and the median stent patency period was 22.1 ± 6.1 mo (95%CI: 9.534.7 mo).
Response of HCC and MPVTT
HCC response was assessed using the mRECIST criteria. During the course of the study, 4.4 ± 3.2 and 2.9 ± 1.2 TACE procedures were performed in groups A and B, respectively. The ORR and DCR in group A were significantly higher than the rates observed in group B (ORR: 45.9% vs 16.1%, P = 0.009; DCR: 67.6% vs 29.0%, P = 0.002).
During the course of the study, the occurrence rate of complications related to MPVTT, such as intrahepa tic metastasis, variceal bleeding, and liver function decompensation, were observed in 15 (40.5%), 6 (16.2%), and 11 (29.7%) patients in group A and 22 (71.0%), 18 (58.1%), and 25 (80.6%) patients in group B, respectively (P = 0.012, P < 0.001, and P < 0.001, respectively).
Treatment-related toxicities
A total of 49 TACErelated AEs occurred in the two groups. The percentages of patients who experienced new ascites, liver dysfunction, and gastrointestinal hemorrhage were significantly higher in group B than in group A.
A total of 140 sorafenib related AEs occurred in 91.2% of patients. Seven patients required a sorafenib dose reduction to 400 mg once daily for grade 3 hand foot skin reactions (4.2%) and grade 3 diarrhea (5.3%) and resumed a regular dose after the AEs subsided. One patient with grade 4 hypertension was subjected to a drug interruption period of 20 d until the AEs subsided (Table 4) .
DISCUSSION
MPVTT is the most important independent predictive factor for poor prognosis of patients with HCC [24] .
Although TACE is effective and safe for intrahepatic primary HCC lesions including few cases of HCC cholangiocellular carcinoma, its benefit in PVTT has less importance, especially in type Ⅲ PVTT or MPVTT. A combined treatment of TACE with novel drugs or other therapies might be a better alternative strategy for HCC with PVTT [2225] . Huang et al [20] reported better survival outcomes with TACE plus 125 Iseed implantation than with TACE alone in patients with type Ⅰ and Ⅱ PVTT. Currently, sorafenib is the recommended standard treatment for advanced HCC with PVTT [26] . Novi et al [27] reported that 15 wk of sorafenib monotherapy played a key role in PVTT revascularization. TACE combined with sorafenib could be a feasible alternative treatment option in patients with HCC and PVTT in the first order or lower order portal vein branches but not in MPVTT [12] . However, a propensityscore analysis reported a significantly shorter OS in the sorafenib group than in the radiotherapy group [28] . According to these reports, the benefits of OS and TTP were lower in patients with MPVTT than in patients with PVTT of firstorder or lower order portal vein branches. The main reason is that the occlusion of MPV is associated with an increased risk of tumor spread, elevated portal venous pressure causing variceal hemorrhage, and decreased portal flow resulting in ascites, jaundice, hepatic encephalopathy, and liver failure [1] . Restoring the flow of obstructed MPV and effectively inhibiting tumor thrombus progression might confer further survival benefit to patients with advanced HCC and MPVTT [13, 21] . The strategy of implantation of 125 I seed strand combined with stent placement and TACE has been reported to treat MPVTT [14, 15] . This method of treatment has two advantages. On one hand, the blood flow to the portal vein is increased immediately and the portal vein pressure elevated by MPV obstruction is reduced effectively after stent deployment. One the other hand, the halflife of the gamma ray emitted by 125 I seeds is 59.4 d. Sustained radiation can inhibit tumor cell growth by inducing apoptosis. Therefore, it is rational to hypothesize that placing a stent to restore the blood flow of obstructed MPV and implantation of 125 I seeds might inhibit the progression of tumor thrombus. This increases the safety of subsequent TACE because of previous concerns that hepatic arterial flow interruption in TACE procedure would result in serious liver necrosis in patients whose hepatic blood supply has been already compromised [29] . Previously, combined brachytherapy with TACE and sorafenib showed greater OS compared to combined brachytherapy with TACE alone in HCC patients with MPVTT [30] . The success rate of TACE with stent placement and 125 I implantation was 88.5%, with a mOS and mTTP of 8.9 mo and 7.9 mo, respectively, both of which were higher than mOS (5.7 mo) and mTTP (5.3 mo) associated with TACE with portal vein stenting alone [6] . Further, in our study addition of sorafenib to the TACE plus portal vein stenting and I implantation increased the OS and TTP to 10.3 mo and 9.0 mo, respectively. This study reported encouraging efficacy for the combination of sorafenib, EVBT, stent placement, and TACE in advanced HCC patients with MPVTT. The OS and TTP were longer in the EVBTstentingTACEsorafenib group than in the TACEsorafenib group. Although our results show moderate sorafenibrelated side effects, they were mostly manageable after TACE and were comparable among the groups. However, TACErelated toxicities were lower in the combination group compared to the sorafenib plus TACE group. The data also demonstrated that the combination therapy has significant benefit in term of ORR and DCR compared with sorafenibTACE. Zhang et al [31] reported that sorafenib monotherapy is a better treatment strategy over sorafenib plus TACE therapy for MPVTT due to the adverse events related to TACE. However, the results of our study suggest that combining EVBT with the sorafenibTACE combination offers added benefits to sorafenib and decreases the toxicities of TACE. After overall analysis of all the side effects observed in the sorafenibTACE group, we believe that combined EVBT with sorafenib and TACE may be a better approach for managing this specific subgroup of patients with advanced HCC and
MPVTT.
The major limitations of this study are the single center retrospective design, which may affect the generalization of results, and small sample size. Further, costbenefit analysis was not performed for the expensive procedures in this study, which may be a topic of interest to be covered in our future studies.
In conclusion, EVBT combined with sorafenib and TACE might be a safe and effective palliative treatment option for MPVTT.
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Research background
Despite the beneficial outcomes of individual therapies, studies pertaining to the clinical outcome of endovascular brachytherapy (EVBT) combined with stent placement, transarterial chemoembolization (TACE), and sorafenib to treat hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT) are scarce.
Research motivation
Recent studies have reported survival benefits in patients with PVTT who underwent combined treatments of TACE with sorafenib, radiotherapy with sorafenib, hepatic arterial infusion chemotherapy with sorafenib, and iodine-125 seed implantation with TACE. However, reports of such combined therapeutic strategies aiming at MPVTT are obscure. According to these previous studies, we aimed to find an effective therapy for HCC patients with MPVTT. 
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